RIQAS

RANDOX INTERNATIONAL QUALITY ASSESSMENT SCHEME

**METHOD QUESTIONNAIRE
URINE TOXICOLOGY PROGRAMME
RQ9139**

Please be aware that the RIQAS Instrument and reagent supplier codes are now in a separate booklet. Please ensure you have a copy of this in order to complete this document.

This document must be retained by participant

REGISTRATION INSTRUCTIONS & RIQAS POLICIES

CRITERIA FOR PARTICIPATION

This programme is available to any laboratory running the Urine Toxicology (Drugs of Abuse) assays listed in this document. Qualitative (screening) and semi-quantitative (confirmatory) results will be accepted on this programme.

INTRODUCTION

Method questionnaires are available for all routine RIQAS Programmes and are reviewed and updated every month, as indicated by the issue date at the bottom of every page. They are designed to allow you to register for this RIQAS Programme and to inform you of RIQAS protocols and policies. It is important that you read and understand all the information in these introductory pages before completing the enrolment document, which forms the basis of your registration and contract with RIQAS. If you have any questions or concerns about any of the information presented in this document, please contact RIQAS either directly or through your local Randox Laboratories representative. RIQAS Calendar dates and information about the RIQAS portfolio of products can be found at www.randox.com/external-quality-assessment.

REGISTRATION INSTRUCTIONS

NOTE: IF A REGISTERED PARTICIPANT DOES NOT PARTICIPATE FOR A CYCLE, THEY WILL BE EXPECTED TO COMPLETE NEW ENROLMENT DOCUMENTS IN ORDER TO RE-JOIN THE PROGRAMME.

METHOD QUESTIONNAIRE:- To be retained by participant

This method questionnaire should be completed and retained by you for your records. Please ensure that you complete the method questionnaire in full. Your details will help us to classify your results correctly and thus provide you with useful statistical data.

In order to fully complete this questionnaire you will also need a copy of the RIQAS Instruments and Reagent Suppliers which is available to download from the Randox website (www.randox.com/external-quality-assessment). Please ensure you have this list available when completing this questionnaire.

Following this introduction section is the method questionnaire which indicates the method codes available for each parameter along with the standard RIQAS unit. On the method questionnaire, for each parameter you wish to run, please tick the method appropriate to you, then state your instrument code, reagent code, and the units that you use in your laboratory if they are different from the RIQAS standard units. If codes are not available for your assay, please state the details of your method clearly in the section at the end of the enrolment document.

Once your method questionnaire has been completed, you must transfer the information onto your enrolment document.

ENROLMENT DOCUMENT:- To be returned to RIQAS

Please be aware that it may take up to 3 weeks to process enrolment documents if you are not entering your own assay details. When registering RIQAS enrolment documents, it is recommended that you state business contact details, rather than personal.

A. LABORATORY REFERENCE NUMBER

On receipt of an enrolment document, each participant is assigned a laboratory reference number which consists of a participant number which is unique to your laboratory and a registration letter which is assigned for each new registration we receive from you. If you are a current or previous participant, please state your participant number on the enrolment document. If you do not have a Laboratory Reference Number, this will be generated by RIQAS when you register for the first time. Please quote this number on all correspondence with RIQAS.

B. CYCLE/PRODUCT REQUIREMENTS

Please tick the cycles you wish to subscribe for. If there is more than one kit/product offered for the programme, please also tick the kit you wish to subscribe for.

C. PRIMARY CONTACT DETAILS

It is important to state the full address details of the Quality Assessment Officer or contact person who will receive all correspondence during the cycle. Please also state the company name of the Randox representative who is supplying you with the RIQAS product under 'Randox Office/Distributor'

Please inform RIQAS of any change to contact details as soon as possible.

D. RIQASNet

RIQASNet is a web-based online method for result entry / method changes and additions of parameters / viewing of released reports. To access RIQASnet go to www.riqas.net. Internet access and login details are required for RIQASNet and Adobe Reader is required for viewing reports. Your initial login information and password will be supplied by RIQAS. Once you have logged in for the first time you will be able to change your RIQASNet password. If you forget your password please follow the 'Forgotten Password' link. Your login information will be based on the 1st email address you supply on your enrolment document. A PDF copy of the report will be sent to this address and can also be sent to 2 other email addresses. These addresses should be stated on your enrolment document.

E. PDF REPORTS

Reports are sent as PDF files. These files can be sent to up to 3 email addresses. Adobe Reader is required to view the reports. The email addresses to which reports are sent can be reviewed and changed on RIQASNet.

F. CUSTOMER DECLARATION

The declaration indicates that by submitting your enrolment document to RIQAS, either directly or via your local Randox representative, you have read and understood the RIQAS policies stated in the most recent Method Questionnaire associated with this programme. You understand that the submission of your enrolment document to RIQAS marks the beginning of an on-going agreement, and you will be automatically enrolled in subsequent cycles of this programme until we receive written confirmation of your cancellation. This should be received 12 weeks prior to the month in which the cycle starts. You understand that you must inform RIQAS of any changes to your contact details, assay details or contract status. You authorise Randox Laboratories Ltd. to send communication related to the products and service provided to the e-mail or postal addresses stated on your submitted enrolment document. You understand that you are permitted to request disclosure of, change or erase personal details held by Randox Laboratories Ltd. at any time. Note: Method questionnaires are updated every month and the issue date is stated on every questionnaire and enrolment document.

G. REGISTRATION OF ASSAY DETAILS

Labs can register their assay details using RIQASNet or can complete the 'Registration of Assay Details' section of the enrolment document. Labs should tick the appropriate box under the 'Registration of Assay Details' section of the enrolment document. If a lab wishes RIQAS to register their assay details, they should complete the Registration of Assay Details section using the codes from this method questionnaire and the Instrument/Reagent Supplier Book.

Once a participant has registered they will receive an email containing their RIQASNet login information. Once you have successfully logged in to RIQASNet you will see your various laboratory reference numbers for each registered programme. If you have opted to add parameters/assay details using RIQASNet, please do so as soon as possible (see below).

If no code is available for your assay, please state the details of your method clearly in the section at the end of the enrolment document or follow the instructions on RIQASNet.

For Ortho-Clinical Diagnostics VITROS registrations, please state the 2 digit slide Generation number for each analyte.

If units other than the standard RIQAS units are used, please specify these in the boxes supplied.

ONCE COMPLETED, THE ENROLMENT DOCUMENT SHOULD BE SENT TO RIQAS **FOR REGISTRATION.**

H. UPDATING ASSAY DETAILS

It is possible to change your unit, method, instrument or reagent classification during a cycle.

Method Changes via RIQASNet: These can be made in the Assay Details section of the Data Entry menu. A list of your registered laboratory reference numbers will appear on screen. Select the laboratory reference number for which you would like to change the assay details. A current list of assay details will appear, click on the appropriate parameter. To change the details click the arrow box on the appropriate details and select a new one. Save the changes and submit them to RIQAS. Changes will not be instantaneously updated on RIQASNet but will be uploaded onto RIQASNet usually within 3 working days. It is possible to submit results and method changes together as method changes will be made before results are entered in to the RIQAS database.

I. ADDITION OF PARAMETERS / ASSAY DETAILS

Adding Parameters via RIQASNet: Parameters can be added using the Assay Details section of the Data Entry menu. A list of your registered laboratory reference numbers will appear on screen. Select the laboratory reference number for which you would like to add the assay details. At the top of the screen is 'Add Parameter'. Click on this and a list of parameters you are not registered for will appear. Select the parameter you wish to add and click the arrow box on the appropriate details and select your assay details. Save the changes and submit them to RIQAS. As above, additions will be available on RIQASnet usually within 3 working days.

ORDERING RIQAS PRODUCTS

Please ensure your purchase order for each cycle is placed with your local Randox representative 12 weeks prior to the month in which the cycle starts. This will ensure sufficient time to process and despatch your kit(s) to you. Participants from UK or Ireland may order products directly from RIQAS with an official order number. Orders received within 12 weeks of the start of the cycle will be processed with an additional administration fee. Current prices of RIQAS products are available from your local Randox Laboratories representative.

It may be possible to order RIQAS products during a cycle, subject to availability. Please contact your local Randox representative for more information.

SHIPPING AND RECEIPT OF RIQAS PRODUCTS

Provided that you have ordered sufficiently in advance, your RIQAS kit(s) will be shipped to you to arrive before the analysis date of the first sample in the kit. If you do not receive your kit(s) before this time, please contact your local Randox representative.

On RIQASNet please access your account and download the relevant Instructions For Use (IFU) document for the programme and cycle purchased. The IFU includes material characteristics, preparation, stability, storage and safety information. On receipt of your RIQAS kit, please check that:

    a) it is the product you ordered

    b) the correct number of samples are present as indicated on the IFU

    c) the samples have the appearance as indicated on the IFU and that none of them are damaged

Please notify your local Randox representative immediately if any of these are incorrect.

Please ensure that the product is immediately stored according to the recommendations on the package labelling.

ASSAY OF SAMPLES & RETURN OF RESULTS

Carefully read the instructions stated on the Instructions for Use (IFU) prior to preparation and assay of RIQAS samples. **These are available on RIQASNet only**. The RIQAS samples should be assayed at the recommended time specified on the IFU. Following appropriate preparation, samples should be treated as routine, unless otherwise stated on the IFU. Please assay the samples on or before the recommended date for analysis and forward your results to RIQAS by no later than **17:00 GMT on the FINAL DATE**, as indicated in the IFU. Results are submitted via RIQASNet, which can be accessed once you have received log in details via email. This will include a link to RIQASNet Instructions for Use.

LATE AND CORRECTED RESULTS

In keeping with the objectives of EQA schemes, participants should be aware that collusion and falsification of results is considered to be unethical and constitutes scientific fraud. RIQAS policies must ensure that a laboratory is unaware of RIQAS means for comparison before submitting their own results. Where a result is not submitted by the final date, a report will be issued, but the missing results will be indicated as "No return" or "N" throughout the RIQAS reports. RIQAS permits the submission of late or corrected results only under the circumstances described below. Requests for the submission of late or corrected results must be submitted in writing and in English on RIQAS Form No. 9277-RQ (either by the participant or their local Randox Representative) and must be approved by RIQAS Management. The form is available on www.riqas.net.

Requests for the submission of late results must be accompanied by evidence that an error has been made, and that the error has not been caused by the participant.

Requests for the correction or removal of erroneous results must be accompanied by evidence that the error was non-analytical, as defined on form 9277-RQ. RIQAS is obliged to inform country-specific regulatory bodies of requests for correction of results (if they request such information for laboratory monitoring purposes).

New reports will be re-issued for late or corrected results only where there has been an error made by Randox Laboratories HQ, Randox representatives or distributors.

LATE RESULTS

In general, late results will not be accepted after the final date.

Late results will only be accepted where there has been an error made by Randox Laboratories HQ, Randox representatives or distributors.

CORRECTED RESULTS

Laboratories may correct results only if it can be determined that the error was non-analytical and where the request for submission is within 4 weeks of the original final date. A laboratory may correct a result under the following circumstances:

☐ Reconstituting a sample in an incorrect volume before analysis

☐ Assaying and/or submitting the results for the wrong sample

☐ Making a transcription error - submission of an analyser print-out indicating that the analysis date was before the final date is required.

DESPATCH OF REPORTS

PDF reports will be emailed within 72 hours of the FINAL DATE and for those registered for RIQASNet the PDF reports will be available on RIQASNet shortly after.

USE OF RIQAS REPORTS

Participants have permission to make copies of their RIQAS reports for internal use and for regulatory purposes only. RIQAS reports must not be duplicated for external use without permission from the RIQAS Scheme Co-ordinator. Under no circumstances should information on RIQAS reports be taken out of context or falsified in any way. Information regarding the format of RIQAS Reports and the monitoring of EQA performance can be found in the RIQAS Brochure at www.randox.com/external-quality-assessment.

CONFIDENTIALITY

Participation in any RIQAS programme is considered to be strictly confidential. Any data transfer or correspondence with participants, either directly or via local Randox representative, will be deemed confidential. Participants should be aware that regulatory authorities have the right to request an assessment of a participant's performance. Where regulatory authorities are to be provided with a participant's results, participants will be notified.

GENERAL DATA PROTECTION REGULATION 2018 & UK DATA PROTECTION ACT 2018

Randox Laboratories Ltd. complies with GDPR and the UK Data Protection Act and holds the minimum information required to maintain the contract with RIQAS customers. Contact details are required in order to effectively provide you with the RIQAS products and services. Participants are not under any obligation to provide personal information to enter into a contract with RIQAS. We recommend that business contact details are provided. All data associated with the provision of RIQAS is collated, stored and processed confidentially and securely, to avoid unlawful processing, accidental loss or damage.

CERTIFICATES OF PARTICIPATION

Complimentary certificates of participation for each RIQAS programme are made available on RIQASNet to participants at the **end of the current cycle**, provided that **at least 50%** of results have been returned. Participants who enrol mid-cycle will be eligible for a Certificate for Participation if they have participated in at least 50% of samples available for the remainder of the cycle since enrolment. The certificate will specify the cycle, programme and the LABORATORY / HOSPITAL NAME which is detailed in the certificate section of RIQASNet. At the end of a cycle, a list of all eligible labs will be exported from RIQASNet and certificates will be created according to these details. Please ensure all certificate details are up to date in your RIQASNet account.

PERFORMANCE SURVEILLANCE OF UK LABS

RIQAS is obligated to identify and report persistent poor performing UK labs to the National Quality Assessment Advisory Panel. Poor performers are identified as those failing to meet performance criteria agreed with NQAAP. The performance criteria is specified in all performance surveillance correspondence with participants, and is also available on request. Participants are initially informed of poor performance by letter. Failure to improve performance will prompt details to be forwarded to NQAAP. All information sent to participants and NQAAP is strictly confidential. Please contact RIQAS if you require further information on Performance Surveillance.

PARTICIPANT FEEDBACK, COMPLAINTS & APPEALS

In order to ensure that RIQAS provides an appropriate and satisfying service, participants are invited to complete a feedback survey on RIQASNet. You may contact us at any time during the cycle, should you have any requests for additional programmes or parameters or comments regarding existing programmes.

RIQAS makes every effort to ensure that the samples provided are clinically challenging to as many laboratory systems as possible. For details, please contact RIQAS either directly or through your local Randox representative.

Should the need arise, participants may raise requests or enquiries through correspondence with the local Randox Laboratories representative or by contacting RIQAS directly. Participants may appeal against the evaluation of their performance by completing a PARTICIPANT APPEALS FORM, 10770-RQ. Participants may raise a complaint in relation to the product or service provided by completing the PARTICIPANT COMPLAINTS FORM, 10772-RQ. These forms are available on RIQASNet, or on request from RIQAS.

SUB-CONTRACTING

RIQAS sub-contracts aspects of the scheme. RIQAS accepts responsibility for the sub-contractors' work and protocols are in place to ensure that sub-contractors are deemed competent.

OUR COMPETENCE AS A PROFICIENCY TESTING PROVIDER

On request, RIQAS is willing to co-operate with participants seeking evidence of our competence as a proficiency testing provider or information on the design and implementation of RIQAS Programmes.

DEVIATION FROM EXISTING POLICIES/SERVICE

If there is any deviation from the existing policies or service, participants will be notified either directly or via their local Randox representative.

COMMUNICATION

As part of the service provided by Randox Laboratories Ltd., participants may be contacted by e-mail regarding updates and new products, in line with Randox Laboratories Ltd. privacy policy, as stated in www.randox.com.

THIS PROGRAMME HAS NOT BEEN ACCREDITED TO
ISO / IEC 17043:2010

Please contact RIQAS at

Tel: +44 (0) 28 9445 4399

E-Mail mail@riqas.com

RIQAS Scheme Co-ordinator: Sally Picton

RANDOX LABORATORIES LTD., 55 Diamond Road, Crumlin, County Antrim, BT29 4QY, United Kingdom

RQ9139 - URINE TOXICOLOGY PROGRAMME
METHOD QUESTIONNAIRE

Creatinine - umol/l

CODE		METHOD
CREAP	☐	Alkaline picrate no deprot.
CRDEP	☐	Alkaline picrate with deprot.
CRPAP	☐	Creatinine PAP method
CREUV	☐	Enzymatic UV method
CRIDM	☐	IDMS traceable
CRERB	☐	Jaffe rate blanked
CRERC	☐	Jaffe rate blanked comp. (-26umol/l)
CREJC	☐	Jaffe rate comp. (-18umol/l)
CREOD	☐	Other Dry Chemistry
CREAO	☐	Other enzymatic methods
CRECP	☐	Roche, Creatinine Plus
CREDT	☐	Vitros, DT60/DT60 II/DTSC II
CREID	☐	Vitros, IDMS traceable

INSTRUMENT CODE [   ]   REAGENT SUPPLIER CODE [   ]

OTHER UNITS, SPECIFY [   ]

Amphetamine Group - ng/ml

CODE		METHOD
AM1CD	☐	CEDIA
AM1CL	☐	Chemiluminescence
AM1CB	☐	Competitive Antibody Binding
AM1DR	☐	DRI-EIA
AM1EL	☐	ELISA
AM1EM	☐	EMIT
AM1EP	☐	EMIT II+
AM1FP	☐	FPIA
AM1HR	☐	HRMS
AM1KM	☐	KIMS
AM1PC	☐	Point of Care
AM1TG	☐	Quidel Triage
AM1RX	☐	Randox Biochip Array Technology

INSTRUMENT CODE [   ]   REAGENT SUPPLIER CODE [   ]

CUT OFF VALUE [   ]   CROSS REACTIVITY FACTOR [   ]

OTHER UNITS, SPECIFY [   ]

d- Amphetamine - ng/ml

CODE		METHOD
AMACD	☐	CEDIA
AMACL	☐	Chemiluminescence
AMACB	☐	Competitive Antibody Binding
AMADR	☐	DRI-EIA
AMAEL	☐	ELISA
AMAEM	☐	EMIT
AMAEP	☐	EMIT II+
AMAFP	☐	FPIA
AMAGC	☐	GC
AMAGM	☐	GC/MS
AMAHR	☐	HRMS
AMAKM	☐	KIMS
AMALM	☐	LC/MS
AMAPC	☐	Point of Care
AMATG	☐	Quidel Triage
AMARX	☐	Randox Biochip Array Technology

INSTRUMENT CODE [   ]   REAGENT SUPPLIER CODE [   ]

CUT OFF VALUE [   ]   CROSS REACTIVITY FACTOR [   ]

OTHER UNITS, SPECIFY [   ]

RQ9139 - URINE TOXICOLOGY PROGRAMME
METHOD QUESTIONNAIRE

d- Methamphetamine - ng/ml

CODE		METHOD
AMDCD	☐	CEDIA
AMDCL	☐	Chemiluminescence
AMDCB	☐	Competitive Antibody Binding
AMDDR	☐	DRI-EIA
AMDEL	☐	ELISA
AMDEM	☐	EMIT
AMDEP	☐	EMIT II+
AMDFP	☐	FPIA
AMDHR	☐	HRMS
AMDKM	☐	KIMS
AMDPC	☐	Point of Care
AMDTG	☐	Quidel Triage
AMDRX	☐	Randox Biochip Array Technology

INSTRUMENT CODE ☐   REAGENT SUPPLIER CODE ☐

CUT OFF VALUE ☐   CROSS REACTIVITY FACTOR ☐

OTHER UNITS, SPECIFY ☐

MDMA - ng/ml

CODE		METHOD
AMMCD	☐	CEDIA
AMMCL	☐	Chemiluminescence
AMMCB	☐	Competitive Antibody Binding
AMMDR	☐	DRI-EIA
AMMEL	☐	ELISA
AMMEM	☐	EMIT
AMMEP	☐	EMIT II+
AMMFP	☐	FPIA
AMMGC	☐	GC
AMMGM	☐	GC/MS
AMMHP	☐	HPLC
AMMHR	☐	HRMS
AMMKM	☐	KIMS
AMMLM	☐	LC/MS
AMMPC	☐	Point of Care
AMMTG	☐	Quidel Triage
AMMRX	☐	Randox Biochip Array Technology

INSTRUMENT CODE ☐   REAGENT SUPPLIER CODE ☐

CUT OFF VALUE ☐   CROSS REACTIVITY FACTOR ☐

OTHER UNITS, SPECIFY ☐

Barbiturates Group - ng/ml

CODE		METHOD
BA1CD	☐	CEDIA
BA1CL	☐	Chemiluminescence
BA1CB	☐	Competitive Antibody Binding
BA1DR	☐	DRI-EIA
BA1EL	☐	ELISA
BA1EM	☐	EMIT
BA1EP	☐	EMIT II+
BA1FP	☐	FPIA
BA1HR	☐	HRMS
BA1KM	☐	KIMS
BA1PC	☐	Point of Care
BA1TG	☐	Quidel Triage
BA1RX	☐	Randox Biochip Array Technology

INSTRUMENT CODE ☐   REAGENT SUPPLIER CODE ☐

CUT OFF VALUE ☐   CROSS REACTIVITY FACTOR ☐

OTHER UNITS, SPECIFY ☐

RQ9139 - URINE TOXICOLOGY PROGRAMME
METHOD QUESTIONNAIRE

Phenobarbital - ng/ml

CODE	METHOD
BAPCD	CEDIA
BAPCL	Chemiluminescence
BAPCB	Competitive Antibody Binding
BAPDR	DRI-EIA
BAPEL	ELISA
BAPEM	EMIT
BAPEP	EMIT II+
BAPFP	FPIA
BAPGC	GC
BAPGM	GC/MS
BAPHP	HPLC
BAPHR	HRMS
BAPKM	KIMS
BAPPC	Point of Care
BAPTG	Quidel Triage
BAPRX	Randox Biochip Array Technology

INSTRUMENT CODE   REAGENT SUPPLIER CODE

CUT OFF VALUE   CROSS REACTIVITY FACTOR

OTHER UNITS, SPECIFY

Secobarbital - ng/ml

CODE	METHOD
BASCD	CEDIA
BASCL	Chemiluminescence
BASCB	Competitive Antibody Binding
BASDR	DRI-EIA
BASEL	ELISA
BASEM	EMIT
BASEP	EMIT II+
BASFP	FPIA
BASHR	HRMS
BASKM	KIMS
BASPC	Point of Care
BASTG	Quidel Triage
BASRX	Randox Biochip Array Technology

INSTRUMENT CODE   REAGENT SUPPLIER CODE

CUT OFF VALUE   CROSS REACTIVITY FACTOR

OTHER UNITS, SPECIFY

Benzodiazepines Group - ng/ml

CODE	METHOD
BE1CD	CEDIA
BE1CL	Chemiluminescence
BE1CB	Competitive Antibody Binding
BE1DR	DRI-EIA
BE1EL	ELISA
BE1EM	EMIT
BE1EP	EMIT II+
BE1FP	FPIA
BE1HR	HRMS
BE1KM	KIMS
BE1PC	Point of Care
BE1TG	Quidel Triage
BE1RX	Randox Biochip Array Technology

INSTRUMENT CODE   REAGENT SUPPLIER CODE

CUT OFF VALUE   CROSS REACTIVITY FACTOR

OTHER UNITS, SPECIFY

RQ9139 - URINE TOXICOLOGY PROGRAMME
METHOD QUESTIONNAIRE

Lorazepam - ng/ml

CODE		METHOD
BELCD	☐	CEDIA
BELCL	☐	Chemiluminescence
BELCB	☐	Competitive Antibody Binding
BELDR	☐	DRI-EIA
BELEL	☐	ELISA
BELEM	☐	EMIT
BELEP	☐	EMIT II+
BELFP	☐	FPIA
BELGC	☐	GC
BELGM	☐	GC/MS
BELHP	☐	HPLC
BELHR	☐	HRMS
BELKM	☐	KIMS
BELLM	☐	LC/MS
BELPC	☐	Point of Care
BELTG	☐	Quidel Triage
BELRX	☐	Randox Biochip Array Technology

INSTRUMENT CODE [   ] REAGENT SUPPLIER CODE [   ]

CUT OFF VALUE [   ] CROSS REACTIVITY FACTOR [   ]

OTHER UNITS, SPECIFY [   ]

Oxazepam - ng/ml

CODE		METHOD
BEOCD	☐	CEDIA
BEOCL	☐	Chemiluminescence
BEOCB	☐	Competitive Antibody Binding
BEODR	☐	DRI-EIA
BEOEL	☐	ELISA
BEOEM	☐	EMIT
BEOEP	☐	EMIT II+
BEOFP	☐	FPIA
BEOHR	☐	HRMS
BEOKM	☐	KIMS
BEOPC	☐	Point of Care
BEOTG	☐	Quidel Triage
BEORX	☐	Randox Biochip Array Technology

INSTRUMENT CODE [   ] REAGENT SUPPLIER CODE [   ]

CUT OFF VALUE [   ] CROSS REACTIVITY FACTOR [   ]

OTHER UNITS, SPECIFY [   ]

Cannabinoids Group - ng/ml

CODE		METHOD
CA1CD	☐	CEDIA
CA1CL	☐	Chemiluminescence
CA1CB	☐	Competitive Antibody Binding
CA1DR	☐	DRI-EIA
CA1EL	☐	ELISA
CA1EM	☐	EMIT
CA1EP	☐	EMIT II+
CA1FP	☐	FPIA
CA1HR	☐	HRMS
CA1KM	☐	KIMS
CA1PC	☐	Point of Care
CA1TG	☐	Quidel Triage
CA1RX	☐	Randox Biochip Array Technology
CA1TL	☐	TLC

INSTRUMENT CODE [   ] REAGENT SUPPLIER CODE [   ]

CUT OFF VALUE [   ] CROSS REACTIVITY FACTOR [   ]

OTHER UNITS, SPECIFY [   ]

RQ9139 - URINE TOXICOLOGY PROGRAMME
METHOD QUESTIONNAIRE

11-NOR-D-9-THC-9-COOH - ng/ml

CODE		METHOD
CATCD	☐	CEDIA
CATCL	☐	Chemiluminescence
CATCB	☐	Competitive Antibody Binding
CATDR	☐	DRI-EIA
CATEL	☐	ELISA
CATEM	☐	EMIT
CATEP	☐	EMIT II+
CATFP	☐	FPIA
CATHR	☐	HRMS
CATKM	☐	KIMS
CATPC	☐	Point of Care
CATTG	☐	Quidel Triage
CATRX	☐	Randox Biochip Array Technology
CATTL	☐	TLC

INSTRUMENT CODE ☐☐☐☐   REAGENT SUPPLIER CODE ☐☐☐

CUT OFF VALUE ☐☐☐☐   CROSS REACTIVITY FACTOR ☐☐☐

OTHER UNITS, SPECIFY ☐☐☐☐

Cocaine Group - ng/ml

CODE		METHOD
CO1CD	☐	CEDIA
CO1CL	☐	Chemiluminescence
CO1CB	☐	Competitive Antibody Binding
CO1DR	☐	DRI-EIA
CO1EL	☐	ELISA
CO1EM	☐	EMIT
CO1EP	☐	EMIT II+
CO1FP	☐	FPIA
CO1HR	☐	HMRS
CO1KM	☐	KIMS
CO1PC	☐	Point of Care
CO1TG	☐	Quidel Triage
CO1RX	☐	Randox Biochip Array Technology

INSTRUMENT CODE ☐☐☐☐   REAGENT SUPPLIER CODE ☐☐☐

CUT OFF VALUE ☐☐☐☐   CROSS REACTIVITY FACTOR ☐☐☐

OTHER UNITS, SPECIFY ☐☐☐☐

Benzoylecgonine - ng/ml

CODE		METHOD
COBCD	☐	CEDIA
COBCL	☐	Chemiluminescence
COBCB	☐	Competitive Antibody Binding
COBDR	☐	DRI-EIA
COBEL	☐	ELISA
COBEM	☐	EMIT
COBEP	☐	EMIT II+
COBFP	☐	FPIA
COBHR	☐	HRMS
COBKM	☐	KIMS
COBPC	☐	Point of Care
COBTG	☐	Quidel Triage
COBRX	☐	Randox Biochip Array Technology

INSTRUMENT CODE ☐☐☐☐   REAGENT SUPPLIER CODE ☐☐☐

CUT OFF VALUE ☐☐☐☐   CROSS REACTIVITY FACTOR ☐☐☐

OTHER UNITS, SPECIFY ☐☐☐☐

RQ9139 - URINE TOXICOLOGY PROGRAMME

METHOD QUESTIONNAIRE

Cotinine - ng/ml

CODE	METHOD
CT1CD	CEDIA
CT1CL	Chemiluminescence
CT1CB	Competitive Antibody Binding
CT1EL	ELISA
CT1EM	EMIT
CT1EP	EMIT II+
CT1FP	FPIA
CT1GC	GC
CT1GM	GC/MS
CT1HP	HPLC
CT1HR	HRMS
CT1KM	KIMS
CT1LM	LC/MS
CT1PC	Point of Care
CT1TG	Quidel Triage
CT1RX	Randox Biochip Array Technology

INSTRUMENT CODE [   ]   REAGENT SUPPLIER CODE   [   ]

CUT OFF VALUE [   ]   CROSS REACTIVITY FACTOR   [   ]

OTHER UNITS, SPECIFY [   ]

Ethanol Group - mg/dl

CODE	METHOD
ETREA	Axsym - REA
ET1CD	CEDIA
ET1CL	Chemiluminescence
ET1CB	Competitive Antibody Binding
ET1DR	DRI-EIA
ET1EL	ELISA
ET1EM	EMIT
ET1EP	EMIT II+
ET1EZ	Enzymatic Method
ET1FP	FPIA
ETIGC	GC
ET1KM	KIMS
ET1PC	Point of Care
ET1TG	Quidel Triage
ET1RX	Randox Biochip Array Technology

INSTRUMENT CODE [   ]   REAGENT SUPPLIER CODE   [   ]

CUT OFF VALUE [   ]   CROSS REACTIVITY FACTOR   [   ]

OTHER UNITS, SPECIFY [   ]

LSD - ng/ml

CODE	METHOD
LS1CD	CEDIA
LS1CL	Chemiluminescence
LS1CB	Competitive Antibody Binding
LS1DR	DRI-EIA
LS1EL	ELISA
LS1EM	EMIT
LS1EP	EMIT II+
LS1FP	FPIA
LS1HR	HRMS
LS1KM	KIMS
LS1PC	Point of Care
LS1TG	Quidel Triage
LS1RX	Randox Biochip Array Technology

INSTRUMENT CODE [   ]   REAGENT SUPPLIER CODE   [   ]

CUT OFF VALUE [   ]   CROSS REACTIVITY FACTOR   [   ]

OTHER UNITS, SPECIFY [   ]

RQ9139 - URINE TOXICOLOGY PROGRAMME

METHOD QUESTIONNAIRE

Methadone - ng/ml

CODE		METHOD
ME1CD	☐	CEDIA
ME1CL	☐	Chemiluminescence
ME1CB	☐	Competitive Antibody Binding
ME1DR	☐	DRI-EIA
ME1EL	☐	ELISA
ME1EM	☐	EMIT
ME1EP	☐	EMIT II+
ME1FP	☐	FPIA
ME1HR	☐	HRMS
ME1KM	☐	KIMS
ME1PC	☐	Point of Care
ME1TG	☐	Quidel Triage
ME1RX	☐	Randox Biochip Array Technology

INSTRUMENT CODE ☐   REAGENT SUPPLIER CODE ☐

CUT OFF VALUE ☐   CROSS REACTIVITY FACTOR ☐

OTHER UNITS, SPECIFY ☐

EDDP - ng/ml

CODE		METHOD
MEECD	☐	CEDIA
MEECL	☐	Chemiluminescence
MEECB	☐	Competitive Antibody Binding
MEEDR	☐	DRI-EIA
MEEEL	☐	ELISA
MEEEM	☐	EMIT
MEEEP	☐	EMIT II+
MEEFP	☐	FPIA
MEEHR	☐	HRMS
MEEKM	☐	KIMS
MEELM	☐	LC/MS
MEEPC	☐	Point of Care
MEETG	☐	Quidel Triage
MEERX	☐	Randox Biochip Array Technology

INSTRUMENT CODE ☐   REAGENT SUPPLIER CODE ☐

CUT OFF VALUE ☐   CROSS REACTIVITY FACTOR ☐

OTHER UNITS, SPECIFY ☐

Opiates Group - ng/ml

CODE		METHOD
OP1CD	☐	CEDIA
OP1CL	☐	Chemiluminescence
OP1CB	☐	Competitive Antibody Binding
OP1DR	☐	DRI-EIA
OP1EL	☐	ELISA
OP1EM	☐	EMIT
OP1EP	☐	EMIT II+
OP1FP	☐	FPIA
OP1HR	☐	HRMS
OP1KM	☐	KIMS
OP1PC	☐	Point of Care
OP1TG	☐	Quidel Triage
OP1RX	☐	Randox Biochip Array Technology
OP1TL	☐	TLC

INSTRUMENT CODE ☐   REAGENT SUPPLIER CODE ☐

CUT OFF VALUE ☐   CROSS REACTIVITY FACTOR ☐

OTHER UNITS, SPECIFY ☐

RQ9139 - URINE TOXICOLOGY PROGRAMME
METHOD QUESTIONNAIRE

Buprenorphine - ng/ml

CODE		METHOD
OPBCD	☐	CEDIA
OPBCL	☐	Chemiluminescence
OPBCB	☐	Competitive Antibody Binding
OPBDR	☐	DRI-EIA
OPBEL	☐	ELISA
OPBEM	☐	EMIT
OPBEP	☐	EMIT II+
OPBFP	☐	FPIA
OPBHR	☐	HRMS
OPBKM	☐	KIMS
OPBPC	☐	Point of Care
OPBTG	☐	Quidel Triage
OPBRX	☐	Randox Biochip Array Technology
OPBTL	☐	TLC

INSTRUMENT CODE ☐   REAGENT SUPPLIER CODE ☐

CUT OFF VALUE ☐   CROSS REACTIVITY FACTOR ☐

OTHER UNITS, SPECIFY ☐

Free Morphine - ng/ml

CODE		METHOD
OPFCD	☐	CEDIA
OPFCL	☐	Chemiluminescence
OPFCB	☐	Competitive Antibody Binding
OPFDR	☐	DRI-EIA
OPFEL	☐	ELISA
OPFEM	☐	EMIT
OPFEP	☐	EMIT II+
OPFFP	☐	FPIA
OPFHR	☐	HRMS
OPFKM	☐	KIMS
OPFPC	☐	Point of Care
OPFTG	☐	Quidel Triage
OPFRX	☐	Randox Biochip Array Technology
OPFTL	☐	TLC

INSTRUMENT CODE ☐   REAGENT SUPPLIER CODE ☐

CUT OFF VALUE ☐   CROSS REACTIVITY FACTOR ☐

OTHER UNITS, SPECIFY ☐

Phencyclidine - ng/ml

CODE		METHOD
PE1CD	☐	CEDIA
PE1CL	☐	Chemiluminescence
PE1CB	☐	Competitive Antibody Binding
PE1DR	☐	DRI-EIA
PE1EL	☐	ELISA
PE1EM	☐	EMIT
PE1EP	☐	EMIT II+
PE1FP	☐	FPIA
PE1HR	☐	HRMS
PE1KM	☐	KIMS
PE1PC	☐	Point of Care
PE1TG	☐	Quidel Triage
PE1RX	☐	Randox Biochip Array Technology

INSTRUMENT CODE ☐   REAGENT SUPPLIER CODE ☐

CUT OFF VALUE ☐   CROSS REACTIVITY FACTOR ☐

OTHER UNITS, SPECIFY ☐

RQ9139 - URINE TOXICOLOGY PROGRAMME

METHOD QUESTIONNAIRE

Propoxyphene Group - ng/ml

CODE		METHOD
PR1CD	☐	CEDIA
PR1CL	☐	Chemiluminescence
PR1CB	☐	Competitive Antibody Binding
PR1DR	☐	DRI-EIA
PR1EL	☐	ELISA
PR1EM	☐	EMIT
PR1EP	☐	EMIT II+
PR1FP	☐	FPIA
PR1HR	☐	HRMS
PR1KM	☐	KIMS
PR1PC	☐	Point of Care
PR1TG	☐	Quidel Triage
PR1RX	☐	Randox Biochip Array Technology

INSTRUMENT CODE ☐   REAGENT SUPPLIER CODE ☐

CUT OFF VALUE ☐   CROSS REACTIVITY FACTOR ☐

OTHER UNITS, SPECIFY ☐

Norpropoxyphene - ng/ml

CODE		METHOD
PRNCD	☐	CEDIA
PRNCL	☐	Chemiluminescence
PRNCB	☐	Competitive Antibody Binding
PRNDR	☐	DRI-EIA
PRNEL	☐	ELISA
PRNEM	☐	EMIT
PRNEP	☐	EMIT II+
PRNFP	☐	FPIA
PRNHR	☐	HRMS
PRNKM	☐	KIMS
PRNPC	☐	Point of Care
PRNTG	☐	Quidel Triage
PRNRX	☐	Randox Biochip Array Technology

INSTRUMENT CODE ☐   REAGENT SUPPLIER CODE ☐

CUT OFF VALUE ☐   CROSS REACTIVITY FACTOR ☐

OTHER UNITS, SPECIFY ☐

TCA Group - ng/ml

CODE		METHOD
TC1CD	☐	CEDIA
TC1CL	☐	Chemiluminescence
TC1CB	☐	Competitive Antibody Binding
TC1DR	☐	DRI-EIA
TC1EL	☐	ELISA
TC1EM	☐	EMIT
TC1EP	☐	EMIT II+
TC1FP	☐	FPIA
TC1HR	☐	HRMS
TC1KM	☐	KIMS
TC1PC	☐	Point of Care
TC1TG	☐	Quidel Triage
TC1RX	☐	Randox Biochip Array Technology

INSTRUMENT CODE ☐   REAGENT SUPPLIER CODE ☐

CUT OFF VALUE ☐   CROSS REACTIVITY FACTOR ☐

OTHER UNITS, SPECIFY ☐

Nortriptyline - ng/ml

CODE		METHOD
TCNCD	☐	CEDIA
TCNCL	☐	Chemiluminescence
TCNCB	☐	Competitive Antibody Binding
TCNDR	☐	DRI-EIA
TCNEL	☐	ELISA
TCNEM	☐	EMIT
TCNEP	☐	EMIT II+
TCNFP	☐	FPIA
TCNHR	☐	HRMS
TCNKM	☐	KIMS
TCNPC	☐	Point of Care
TCNTG	☐	Quidel Triage
TCNRX	☐	Randox Biochip Array Technology

INSTRUMENT CODE ☐   REAGENT SUPPLIER CODE ☐

CUT OFF VALUE ☐   CROSS REACTIVITY FACTOR ☐

OTHER UNITS, SPECIFY ☐